Biocon signs 10-year Brazil supply deal for Pertuzumab breast cancer drug

Biocon Limited has secured a 10-year supply contract in Brazil for Pertuzumab, a monoclonal antibody used to treat HER2-positive breast cancer, after signing a partnership agreement with Brazilian public pharmaceutical laboratory Bahiafarma and biotechnology company Bionovis.

The Biocon-Bahiafarma-Bionovis consortium has received 100% allocation under Brazil's 10-year Productive Development Partnership (PDP) programme for Pertuzumab, giving it exclusive access to the country's public healthcare market, which accounts for around 70% of demand for the drug.

Under the agreement, Biocon will receive milestone payments and a share of revenues generated from the Brazil PDP opportunity over the 10-year period. As part of the PDP framework, Pertuzumab will undergo phased localisation in Brazil over the medium to long term.


The agreement marks an important step in expanding access to the HER2-positive breast cancer therapy while supporting local production capabilities in Brazil.

Pertuzumab is currently not manufactured locally in Brazil and represents a significant expenditure for the country's Unified Health System (SUS).

Shreehas Tambe, CEO & Managing Director, Biocon, said, “Brazil is an important country for Biocon, and our journey here reflects the transformative potential of strong partnerships in building local capabilities and expanding access to high-quality, affordable medicines. This long-term supply contract for Pertuzumab marks a significant milestone in this journey, enabling us to reach more patients living with HER2-positive breast cancer and address an important healthcare need at scale. In partnership with Bahiafarma and Bionovis, we are bringing together science, innovation, manufacturing excellence and local expertise to create a more sustainable pathway for access to this important cancer therapy. Together, we are not only supporting better patient outcomes but also helping build a stronger, more resilient healthcare ecosystem in Brazil.”

Ceuci Nunes, CEO, Bahiafarma, said, “We celebrate the conclusion of this stage with the certainty that we are advancing in a strategic project for public health. It is the result of a work built in partnership and that paves the way for the incorporation of a highly complex technology, contributing to Brazil strengthening its capacity to produce essential medicines for its Unified Health System (SUS)."

The PDP provides the consortium with exclusive access to Brazil's public healthcare market, which accounts for approximately 70% of the country's demand for Pertuzumab. It also supports the long-term adoption of Biocon's product within Brazil's public oncology network.

As part of the partnership, the product will undergo phased localisation in Brazil in the medium to long term. The arrangement is expected to bring together Biocon's biopharmaceutical capabilities with Bahiafarma's role as a public pharmaceutical laboratory and Bionovis' focus on complex biological medicines and biosimilars.